Patents by Inventor Kallanthottathil G. Rajeev

Kallanthottathil G. Rajeev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    Publication number: 20190167800
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Application
    Filed: September 6, 2018
    Publication date: June 6, 2019
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION
    Publication number: 20190134206
    Abstract: This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.
    Type: Application
    Filed: August 3, 2018
    Publication date: May 9, 2019
    Inventors: Jayaprakash K. Nair, Alexander V. Kel'in, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Therapeutic compositions
    Patent number: 10273477
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: April 30, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • Biodegradable lipids for the delivery of active agents
    Patent number: 10266484
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: April 23, 2019
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Martin Maier, Muthusamy Jayaraman, Shigeo Matsuda, Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Akin Akinc, Thomas A. Baillie
  • Targeting Lipids
    Publication number: 20190099493
    Abstract: The present invention provides targeting lipids of structure where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.
    Type: Application
    Filed: October 10, 2017
    Publication date: April 4, 2019
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Muthusamy Jayaraman
  • Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
    Patent number: 10208307
    Abstract: The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: February 19, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tracy Zimmermann, Amy Chan, Vasant Jadhav, Martin Maier, Kallanthottathil G. Rajeev
  • CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION
    Publication number: 20190048344
    Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 14, 2019
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, Jayaprakash K. Nair, Muthusamy Jayaraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
  • MODIFIED RNAi AGENTS
    Publication number: 20190038768
    Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 7, 2019
    Inventors: Kallanthottathil G. RAJEEV, Tracy ZIMMERMANN, Muthiah MANOHARAN, Martin MAIER, Satyanarayana KUCHIMANCHI, Klaus CHARISSE
  • COMPOSITIONS FOR NUCLEIC ACID DELIVERY
    Publication number: 20180369384
    Abstract: The present invention is based, in part, upon the discovery of charged lipids that provide advantages when used in lipid particles for the in vivo delivery of a therapeutic agent. As such, described herein are compounds useful for delivering a nucleic acid to a cell.
    Type: Application
    Filed: May 16, 2017
    Publication date: December 27, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Mamta Kapoor, Rajesh Kumar Kainthan
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180346910
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 6, 2018
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • 5? phosphate mimics
    Patent number: 10131908
    Abstract: The present invention provides nucleosides and oligonucleotides comprising a 5? phosphate mimics of formula (IVc) or (Vc), One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: November 20, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Marija Prhavc, Ivan Zlatev
  • iRNA AGENTS WITH BIOCLEAVABLE TETHERS
    Publication number: 20180327744
    Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV
  • CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
    Publication number: 20180326070
    Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.
    Type: Application
    Filed: November 20, 2017
    Publication date: November 15, 2018
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jayaprakash NAIR, Martin MAIER
  • PCSK9 iRNA compositions and methods of use thereof
    Patent number: 10125369
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: November 13, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Anna Borodovsky, Kallanthottathil G. Rajeev, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Muthiah Manoharan, Stuart Milstein
  • RNAi agents modified at the 4?-C position
    Patent number: 10119136
    Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more 4?-modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: November 6, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Shigeo Matsuda, Kallanthottathil G. Rajeev, Ivan Zlatev
  • Lipids and compositions for the delivery of therapeutics
    Patent number: 10117941
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: November 6, 2018
    Assignee: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • iRNA agents with biocleavable tethers
    Patent number: 10119138
    Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 6, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Carbohydrate conjugated RNA agents and process for their preparation
    Patent number: 10086081
    Abstract: This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: October 2, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. Nair, Alexander V. Kelin, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS
    Publication number: 20180221494
    Abstract: The invention relates to compositions and methods for site-specific delivery of nucleic acids by combining them with targeting ligands and endosomolytic components.
    Type: Application
    Filed: December 11, 2017
    Publication date: August 9, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Muthusamy Jayaraman
  • METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS
    Publication number: 20180221510
    Abstract: A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unsaturation can include cycloalkyl groups, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl groups. The lipid particle is suitable for delivering an active agent.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 9, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, Michael E. Jung